JPWO2021041373A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021041373A5
JPWO2021041373A5 JP2022513859A JP2022513859A JPWO2021041373A5 JP WO2021041373 A5 JPWO2021041373 A5 JP WO2021041373A5 JP 2022513859 A JP2022513859 A JP 2022513859A JP 2022513859 A JP2022513859 A JP 2022513859A JP WO2021041373 A5 JPWO2021041373 A5 JP WO2021041373A5
Authority
JP
Japan
Prior art keywords
expression vector
pharmaceutical composition
seq
cells
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513859A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545967A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047733 external-priority patent/WO2021041373A1/en
Publication of JP2022545967A publication Critical patent/JP2022545967A/ja
Publication of JPWO2021041373A5 publication Critical patent/JPWO2021041373A5/ja
Pending legal-status Critical Current

Links

JP2022513859A 2019-08-26 2020-08-25 完全ヒト翻訳後修飾抗VEGF Fabを用いる糖尿病性網膜症の処置 Pending JP2022545967A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962891799P 2019-08-26 2019-08-26
US62/891,799 2019-08-26
US201962902352P 2019-09-18 2019-09-18
US62/902,352 2019-09-18
US202063004258P 2020-04-02 2020-04-02
US63/004,258 2020-04-02
PCT/US2020/047733 WO2021041373A1 (en) 2019-08-26 2020-08-25 Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab

Publications (2)

Publication Number Publication Date
JP2022545967A JP2022545967A (ja) 2022-11-01
JPWO2021041373A5 true JPWO2021041373A5 (xx) 2023-09-01

Family

ID=72473961

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022513859A Pending JP2022545967A (ja) 2019-08-26 2020-08-25 完全ヒト翻訳後修飾抗VEGF Fabを用いる糖尿病性網膜症の処置

Country Status (12)

Country Link
US (1) US20220280608A1 (xx)
EP (1) EP4021936A1 (xx)
JP (1) JP2022545967A (xx)
KR (1) KR20220051246A (xx)
CN (1) CN114502197A (xx)
AU (1) AU2020336314A1 (xx)
BR (1) BR112022003811A2 (xx)
CA (1) CA3149401A1 (xx)
IL (1) IL290863A (xx)
MX (1) MX2022002366A (xx)
TW (1) TW202122419A (xx)
WO (1) WO2021041373A1 (xx)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202005618WA (en) 2017-12-19 2020-07-29 Akouos Inc Aav-mediated delivery of therapeutic antibodies to the inner ear
WO2024073669A1 (en) 2022-09-30 2024-04-04 Regenxbio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
JP3817739B2 (ja) 1994-12-29 2006-09-06 マサチューセッツ・インスティテュート・オブ・テクノロジー キメラdna結合性タンパク質
KR19990022651A (ko) 1995-06-07 1999-03-25 데이비드 엘. 버스테인 생물학적 사건에 대한 라파마이신 기재 조절방법
CA2300376A1 (en) 1997-08-26 1999-03-04 Ariad Gene Therapeutics, Inc. Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain
IL134643A0 (en) 1997-08-27 2001-04-30 Ariad Gene Therapeutics Inc Chimeric transcriptional activators and compositions and uses related thereto
EP1045915A2 (en) 1998-01-15 2000-10-25 Ariad Gene Therapeutics, Inc. Regulation of biological events using multimeric chimeric proteins
EP1053241A1 (en) 1998-02-13 2000-11-22 President And Fellows Of Harvard College Novel dimerizing agents, their production and use
JP4827353B2 (ja) 1999-08-09 2011-11-30 ターゲティッド ジェネティクス コーポレイション 鎖内塩基対を形成するような配列の設計による、組換えウイルスベクターからの一本鎖の異種ヌクレオチド配列の発現の増大
US7067526B1 (en) 1999-08-24 2006-06-27 Ariad Gene Therapeutics, Inc. 28-epirapalogs
SG157224A1 (en) 2001-11-13 2009-12-29 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
EP1453547B1 (en) 2001-12-17 2016-09-21 The Trustees Of The University Of Pennsylvania Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor
DK3211085T3 (da) 2003-09-30 2021-06-21 Univ Pennsylvania Klader af adeno-associeret virus (aav), sekvenser, vektorer indeholdende disse og anvendelser deraf
DK2359867T3 (en) 2005-04-07 2015-01-05 Univ Pennsylvania A method for increasing an AAV vector function
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
US8734809B2 (en) 2009-05-28 2014-05-27 University Of Massachusetts AAV's and uses thereof
US8927514B2 (en) 2010-04-30 2015-01-06 City Of Hope Recombinant adeno-associated vectors for targeted treatment
US8628966B2 (en) 2010-04-30 2014-01-14 City Of Hope CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer
WO2012057363A1 (ja) 2010-10-27 2012-05-03 学校法人自治医科大学 神経系細胞への遺伝子導入のためのアデノ随伴ウイルスビリオン
JP6042825B2 (ja) 2011-02-10 2016-12-14 ザ・ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 改変された形質導入プロファイルを有するウイルスベクターならびにその製造および使用の方法
EP3693025B1 (en) 2011-04-22 2021-10-13 The Regents of The University of California Adeno-associated virus virions with variant capsid and methods of use thereof
EP2748185A1 (en) 2011-08-24 2014-07-02 The Board of Trustees of The Leland Stanford Junior University New aav capsid proteins for nucleic acid transfer
US9677088B2 (en) 2012-05-09 2017-06-13 Oregon Health & Science University Adeno associated virus plasmids and vectors
ES2729166T3 (es) 2012-05-24 2019-10-30 Altaviz Llc Inyector de fluido viscoso
JP2016514152A (ja) 2013-03-13 2016-05-19 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア アデノ随伴ウイルスベクターおよびその使用の方法
EP3044318B1 (en) 2013-09-13 2019-05-01 California Institute of Technology Selective recovery
CN115141260A (zh) 2013-10-11 2022-10-04 马萨诸塞眼科耳科诊所 预测祖先病毒序列的方法及其用途
US10746742B2 (en) 2014-04-25 2020-08-18 Oregon Health & Science University Methods of viral neutralizing antibody epitope mapping
US10064752B2 (en) 2014-09-11 2018-09-04 Orbit Biomedical Limited Motorized suprachoroidal injection of therapeutic agent
EP3223760B1 (en) 2014-11-28 2020-01-08 Visionisti OY Ocular therapeutics tool
USD878575S1 (en) 2015-11-24 2020-03-17 Visionisti Oy Hand operated medical instrument
SG10202008378UA (en) 2016-04-15 2020-10-29 Regenxbio Inc Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
SG11201808426XA (en) 2016-04-15 2018-10-30 Univ Pennsylvania Compositions for treatment of wet age-related macular degeneration
CA3076905A1 (en) 2017-09-27 2019-04-04 The Johns Hopkins University Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab
CA3079565A1 (en) * 2017-10-18 2019-04-25 Regenxbio Inc. Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified vegf-trap
EP3703792B1 (en) 2017-11-04 2023-10-11 Altaviz, LLC Injection devices and methods for making them
US10912883B2 (en) 2017-11-04 2021-02-09 Altaviz, Llc Gas-powered fluid injection system

Similar Documents

Publication Publication Date Title
JP7046828B2 (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP2022153418A5 (xx)
RU2018142768A (ru) Варианты капсидов аденоассоциированного вируса и способы их применения
JP2021503914A5 (xx)
US20180353614A1 (en) VE-PTP Extracellular Domain Antibodies Delivered by a Gene Therapy Vector
FI3717636T3 (fi) Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä
JP2024016207A (ja) 滲出型加齢性黄斑変性の治療のための組成物
JP2022137244A (ja) アフリベルセプトを含むaav2バリアントを使用したamdの処置
TWI581801B (zh) 治療血管新生相關之眼疾之組合物及方法
JP2015523060A5 (xx)
CN110423281B (zh) 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物
CN113121655B (zh) 眼部和肌肉特异靶向型腺相关病毒载体及其应用
WO2017106244A1 (en) Compositions and methods for regulatable antibody expression
CN117467025B (zh) 一种抗vegf和补体双功能融合蛋白及其应用
CN113121653B (zh) 肌肉和视网膜特异性的新型腺相关病毒衣壳蛋白
JPWO2020206098A5 (xx)
JPWO2021041373A5 (xx)
JPWO2021071835A5 (xx)
Wu et al. Half-Life Extension Enhances Drug Efficacy in Adeno-Associated Virus Delivered Gene Therapy
US20240189448A1 (en) Dna structure for treating ocular pathologies
Chan Association for Research in Vision and Ophthalmology (ARVO) 2017 Annual Meeting. Baltimore, Maryland, USA-May 7-11, 2017
WO2023028004A1 (en) Compositions and methods for transgene expression
JP2024525186A (ja) 網膜障害
JPWO2020180951A5 (xx)
CN116710137A (zh) 用于在治疗眼部疾病的方法中使用的vegf拮抗剂